Ajalopram

Ajalopram

escitalopram

Manufacturer:

AJ Research & Pharma

Distributor:

AJ Research & Pharma
Concise Prescribing Info
Contents
Escitalopram
Indications/Uses
Major depressive episodes, panic disorder w/ or w/o agoraphobia, social & generalised anxiety disorder, obsessive-compulsive disorder (OCD).
Dosage/Direction for Use
Major depressive episodes, generalised anxiety disorder & OCD 10 mg once daily, may be increased to max: 20 mg daily. Panic disorder w/ or w/o agoraphobia Initially 5 mg for 1st wk before increasing to 10 mg daily. May be further increased to max: 20 mg daily. Social anxiety disorder 10 mg once daily, may be subsequently decreased to 5 mg or increased to max: 20 mg daily. Elderly >65 yr Initially 5 mg once daily, may be increased to 10 mg daily. Mild or moderate hepatic impairment, patient known to be poor CYP2C19 metabolisers Initially 5 mg daily for 1st 2 wk, may be increased to 10 mg daily.
Administration
May be taken with or without food: Place tab on the tongue & allow to disintegrate. May be swallowed w/o water.
Contraindications
Hypersensitivity. Patients w/ known QT interval prolongation or congenital long QT syndrome. Concomitant treatment w/ nonselective, irreversible MAOIs; reversible MAO-A inhibitors (eg, moclobemide) or reversible nonselective MAOI (eg, linezolid); medicinal products prolonging QT interval.
Special Precautions
Discontinue use if serotonin syndrome or increased seizure frequency occurs. Avoid use in patients w/ unstable epilepsy. Monitor for clinical worsening, suicidal behaviour or thoughts & unusual changes in behaviour. Patients w/ CHD; hypokalaemia, pre-existing QT interval prolongation or other cardiac diseases; significant bradycardia, recent acute MI or uncompensated heart failure; known bleeding tendencies; angle-closure glaucoma or history of glaucoma. Paradoxical anxiety; history of mania/hypomania; diabetes; akathisia/psychomotor restlessness. Correct electrolyte disturbances prior to treatment. Closely monitor patients w/ controlled epilepsy. Concomitant use w/ drugs causing hyponatraemia; oral anticoagulants, medicinal products affecting platelet function eg, atypical antipsychotics, phenothiazines, TCAs, ASA, NSAIDs, ticlopidine, dipyridamole; medicinal products w/ serotonergic effects eg, sumatriptan or other triptans, tramadol, tryptophan; St. John's wort; electroconvulsive therapy. Avoid abrupt discontinuation. May affect ability to drive & use machines. Cirrhotic & female patients. Severe hepatic & renal impairment (CrCl <30 mL/min). Not to be used during pregnancy. Not recommended during lactation. Not to be used in childn & adolescents <18 yr. Elderly.
Adverse Reactions
Headache; nausea. Decreased/increased appetite, increased wt; anxiety, restlessness, abnormal dreams, decreased libido, female anorgasmia; insomnia, somnolence, dizziness, paraesthesia, tremor; sinusitis, yawning; diarrhoea, constipation, vomiting, dry mouth; increased sweating; arthralgia, myalgia; ejaculation disorder, male impotence; fatigue, pyrexia.
Drug Interactions
Serotonin syndrome w/ irreversible nonselective MAOIs; reversible selective MAO-A inhibitor eg, moclobemide; reversible nonselective MAOI eg, linezolid; irreversible selective MAO-B inhibitor eg, selegiline; serotonergic medicinal products eg, tramadol, sumatriptan, other triptans. Lowered seizure threshold w/ TCAs, neuroleptics (eg, phenothiazines, thioxanthenes, butyrophenones), mefloquine, bupropion, tramadol. Enhanced effects w/ lithium, tryptophan. Increased AR incidence w/ St. John's wort. Altered anticoagulant effect w/ oral anticoagulants. Increased bleeding tendencies w/ NSAIDs. Increased risk of malignant arrhythmias w/ hypokalaemia-hypomagnesaemia-inducing medicinal products. Increased plasma conc w/ omeprazole, cimetidine; desipramine, metoprolol. Medicinal products prolonging QT interval eg, class IA & III antiarrhythmics; antipsychotics eg, phenothiazine derivatives, pimozide, haloperidol; TCAs; certain antimicrobial agents eg, sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, halofantrine; certain antihistamines eg, astemizole, mizolastine. Concomitant use w/ esomeprazole, fluvoxamine, lansoprazole, ticlopidine; flecainide, propafenone, clomipramine, nortriptyline, risperidone, thioridazine; CYP2C19-metabolised medicinal products. Not to be combined w/ alcohol.
MIMS Class
Antidepressants
ATC Classification
N06AB10 - escitalopram ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.
Presentation/Packing
Form
Ajalopram orodispersible tab 10 mg
Packing/Price
14's;30's
Form
Ajalopram orodispersible tab 15 mg
Packing/Price
14's
Form
Ajalopram orodispersible tab 20 mg
Packing/Price
14's
Form
Ajalopram orodispersible tab 5 mg
Packing/Price
14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in